Anavex Life Sciences Corp.

NasdaqGS:AVXL Rapporto sulle azioni

Cap. di mercato: US$479.1m

Anavex Life Sciences Dividendo

Dividendo criteri di controllo 0/6

Anavex Life Sciences non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore1.9%
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Utile per azione-US$0.49
Previsione del rendimento del dividendon/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)

Oct 08

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Jul 29

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Jul 17
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Apr 01
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Sep 19
Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

May 10
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Jan 16
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Oct 01
We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Sep 19

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Sep 07

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Aug 09

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Jun 17
We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex: Increasing Shareholder Value Against All Odds

May 31

Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease

Mar 23

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Mar 03
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease

Feb 09

Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity

Feb 02

Anavex: 2022 Has Major, Pivotal Catalysts

Jan 17

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Nov 16
Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?

Nov 05

Anavex Life Sciences: Still Room To Run

Aug 29

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Jul 30
Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Anavex: A Catalyst-Rich Year

Jul 05

Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers

Jun 21

Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease

Jun 14

Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment

Jun 08

Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease

Apr 28

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Apr 16
Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Anavex shares up 65% in morning trading continuing hot streak

Feb 04

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di AVXL siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di AVXL siano aumentati.


Rendimento dei dividendi rispetto al mercato

Anavex Life Sciences Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di AVXL rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (AVXL)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.4%
Media del settore (Biotechs)1.9%
Analista previsionale (AVXL) (fino a 3 anni)n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di AVXL rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di AVXL rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.


Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di AVXL per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.


Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché AVXL non ha segnalato alcun pagamento.


Scoprire le società che pagano dividendi forti